Interferon beta-1a improves urinary symptoms, reduces proviral load, and modifies the immune response in a patient with HAM/TSP

Davi Costa, Michael A Sundberg, Lucia Passos, Andre Luiz Muniz, Silvane Santos

Research output: Contribution to journalArticlepeer-review

Abstract

The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In this paper, we describe a 55-year-old female patient with HAM/TSP who was treated with interferon beta-1a. This patient, in comparison to 20 female patients with HAM/TSP who were not treated, showed improvement in urinary symptoms over four years of therapy, as well as a reduction in HTLV-1 proviral load and serum cytokine levels typically observed in HAM/TSP. This improved outcome merits further controlled studies on the use and efficacy of interferon beta-1a as a therapy for HAM/TSP.
Original languageEnglish (US)
JournalCase Reports in Neurological Medicine
DOIs
StatePublished - Aug 2012

Fingerprint Dive into the research topics of 'Interferon beta-1a improves urinary symptoms, reduces proviral load, and modifies the immune response in a patient with HAM/TSP'. Together they form a unique fingerprint.

Cite this